Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival

Background: Multiple myeloma is a malignant haematological neoplasm characterised by clonal proliferation of plasma cells, with a complex clinical picture, and a significant impact on patient survival, in which the prognosis evaluation of patients is of great importance. Objectives: In this single-c...

Full description

Saved in:

Bibliographic Details
Main Authors:	Melania Carlisi, Rosalia Lo Presti, Corinne Spoto, Salvatrice Mancuso, Sergio Siragusa, Gregorio Caimi
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-11-01
Series:	Therapeutic Advances in Hematology
Online Access:	https://doi.org/10.1177/20406207241298865
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exciting New Data in Newly Diagnosed Multiple Myeloma
by: Kaveh Samii
Published: (2022-10-01)

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL
by: Vincenzo Accurso, et al.
Published: (2020-01-01)

Can you diagnose immune thrombocytopenia in myeloma? A case of thrombocytopenia in a patient with multiple myeloma
by: Cláudia Diogo, et al.
Published: (2024-11-01)

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma
by: Grace M. Ferri, et al.
Published: (2025-01-01)

Analysis of smoldering multiple myeloma according to the target of the monoclonal immunoglobulin of patients
by: Sylvie Hermouet, et al.
Published: (2024-12-01)

The correlation between serum bone metabolism indexes and bone disease and survival in newly diagnosed multiple myeloma patients
by: Linlin Huang, et al.
Published: (2024-12-01)

IMPeTUs parameters correlate with clinical features in newly diagnosed multiple myeloma
by: Shuaishuai Xu, et al.
Published: (2024-12-01)

Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma
by: Benjamin A. Derman, et al.
Published: (2018-01-01)

Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
by: Wen‐Ying Lin, et al.
Published: (2023-02-01)

The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors
by: Salvatrice Mancuso, et al.
Published: (2020-01-01)

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
by: Naomi van Hest, et al.
Published: (2023-01-01)

MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: Francesca Fazio, et al.
Published: (2023-08-01)

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy
by: Luciano J. Costa, et al.
Published: (2025-02-01)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
by: Cristina De Ramón, et al.
Published: (2024-12-01)

Mothers balancing work and family: the associations with emotional well-being, sleep–wake problems and the role of basic needs
by: Rosalia Olivieri, et al.
Published: (2024-12-01)

The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
by: Yuxin Liu, et al.
Published: (2024-10-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

METHOD AND ALGORITHMS OF CALCULATION OF PARAMETERS OF RELIABILITY IN ACCORDANCE WITH MULTIVARIATE DATA
by: E. M. Farhadzadeh, et al.
Published: (2017-01-01)

3 years survival of patients with multiple myeloma.
by: Julio Dámaso Fernández Águila, et al.
Published: (2006-12-01)

Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
by: Xiaoqing Dong, et al.
Published: (2024-12-01)

A Nomogram Based on Circulating Inflammatory Factors for Predicting Prognosis of Newly Diagnosed Multiple Myeloma Patients
by: Wang M, et al.
Published: (2025-02-01)

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
by: Manisha Bhutani, et al.
Published: (2025-02-01)

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries
by: Anas Hamad, et al.
Published: (2024-07-01)

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis
by: Elisa Gelli, et al.
Published: (2024-11-01)

Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy
by: Senhua Song, et al.
Published: (2024-12-01)

FORMATION OF COSTS AND CALCULATION OF THE COST OF MAINTENANCE OF IMPLEMENTED LABORATORY MEDICAL EQUIPMENT
by: E. Shapoval, et al.
Published: (2017-07-01)

Analysis of coagulation alteration and its correlation with β2-microglobulin in 371 patients with newly diagnosed multiple myeloma
by: Miao Hu, et al.
Published: (2024-12-01)

Incidental Discovery of Multiorgan Extramedullary Plasmacytomas in the Setting of Newly Diagnosed Multiple Myeloma and Delayed Hemolytic Transfusion Reaction
by: Joselle Cook, et al.
Published: (2017-01-01)

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

The effectiveness of play therapy according levy approach in reduction of anxiety in children with diagnosed cancer
by: Majid Mahmood alilo, et al.
Published: (2015-04-01)

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Olga Lytvynova, et al.
Published: (2024-09-01)

Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma
by: Francisco-Javier Cepeda-Piorno, et al.
Published: (2022-01-01)

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma
by: Wenjiao Tang, et al.
Published: (2023-02-01)

Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients
by: Yichuan Song, et al.
Published: (2024-11-01)

The characteristics of patients with multiple myeloma surviving over 10 years
by: Beihui Huang, et al.
Published: (2024-11-01)

Retrospective study of the frequency of diagnosing diffuse changes in the liver parenchyma according to the results of radiological studies
by: N.Yu. Ziuz, et al.
Published: (2024-12-01)

DICAUVACOOP: A Software Tool to Calculate and Visualize Differentiated Payment According to Grape Quality
by: Javier Ruiz-Serrano, et al.
Published: (2025-01-01)

Laboratory Test and Study and Numerical Calculation and Analysis for Characteristics of Expansive Soil at Macha River
by: ZHANG Tianqi, et al.
Published: (2020-01-01)

Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01)